Get the Daily Brief
Latest Biotech News
HIV prevention access and real-world adherence barriers
A new systematic review highlights why HIV prevention pills are still failing to reach many adolescents and young people. Published in BMC Health, the analysis points to stigma, restrictive...
Two-drug HIV therapy reaches lymph node reservoirs
A randomized trial using in situ viral imaging and mass spectrometry reports that first-line dolutegravir/lamivudine can penetrate lymph node tissue and coincides with a rapid decline in...
COVID-19 immunity wanes with rising community transmission
A prospective cohort study from the Dominican Republic finds antibody levels associated with protection against SARS-CoV-2 infection shift upward during periods of high community...
Home-based monitoring can cut postoperative complications – only with clinician review
A pooled analysis presented at ANESTHESIOLOGY 2026 reports that app-based postoperative monitoring was associated with fewer serious complications and emergency room visits, plus fewer...
Cancer surgery choice reshapes long-term colorectal cancer risk after appendicitis
A matched study of more than 30,000 appendicitis patients reports that appendectomy is tied to a sharply lower later colorectal cancer risk than antibiotics alone. The analysis finds a 58% lower...
Proximal biomarker: inflammation index plus staging predicts lung cancer survival
A BMC Cancer study fuses a blood-based inflammation index with clinical variables including age, smoking history, and AJCC stage to build a lung cancer survival model. The model held up under...
Off-the-shelf CAR T success depends on immune rejection and CAR T cell fitness
An MD Anderson study reports that immune rejection and the intrinsic fitness of donor-derived CAR T cells determine which patients benefit from off-the-shelf CAR T therapies. The work points to...
Mount Sinai wins $20.7M to build next-generation respiratory mRNA vaccine platform
Mount Sinai received a five-year, $20.7 million agreement to develop the VITAL vaccine platform, starting with an intranasal H5N1 mRNA prototype aimed at targeting respiratory immune cells. The...
Checkpoint inhibition side effects are not equal for survival
A new study challenges the common oncology assumption that all immune checkpoint inhibitor side effects are uniformly associated with better survival. The analysis suggests survival impact varies...
Rapid point-of-care diagnostics: microfluidic platform enables multidimensional profiling
A programmable smartphone-integrated microfluidic platform reports attomolar sensitivity and accuracy above 95% across molecular and protein assays, reframing point-of-care diagnostics beyond...
Glioblastoma drug development shifts toward biomarker-guided combinations
A new Oncoscience perspective maps the 2025–2026 glioblastoma clinical trial pipeline across four mechanistic domains, highlighting how developers are increasingly pairing biomarker-selected...
New diagnostic signal for blood cancers and risk stratification
Scientists mapped two distinct T cell exhaustion programs driving acute myeloid leukemia (AML) relapse, distinguishing self-derived exhausted T cells from donor-derived counterparts before and...
Targeted CRISPR screen identifies a vulnerability in GNAQ-mutant eye cancer
CRISPR-based synthetic lethal screening has identified the acetyltransferases p300 and CBP as essential chromatin partners for YAP-driven transcription in GNAQ-mutant uveal melanoma. The work...
Immunotherapy-resistance biology resurfaces as a cancer treatment limiter
A new MD Anderson study reports that success with off-the-shelf CAR T therapies is shaped by pre-existing immune rejection and the intrinsic fitness of donor-derived CAR T cells. The work frames...
H5N1 vaccine platform funding and early clinical path
Mount Sinai won a five-year, $20.7 million agreement to develop its VITAL vaccine platform, with an intranasal H5N1 mRNA prototype designed to target antigen expression to respiratory immune...
PR3-ANCA pulmonary-renal syndrome sees rituximab rescue after standard failure
A case report describes rituximab controlling severe PR3-ANCA pulmonary-renal syndrome in a dialysis-dependent patient after conventional induction therapy failed. The report highlights a...
Peripheral artery disease burden ties to metabolic risk signals in China
New research reports a surging peripheral artery disease (PAD) burden in China, with metabolic risk factors identified as drivers of the worsening outlook. The analysis frames PAD as increasingly...
CagriSema meta-analysis adds dose-specific efficacy signal in type 2 diabetes
A new meta-analysis of six randomized trials reports that CagriSema significantly lowers HbA1c, body weight, and blood pressure in type 2 diabetes, with efficacy and tolerability differences...
Microfluidic point-of-care platform boosts multi-analyte diagnostic performance
Researchers reported a programmable, smartphone-integrated microfluidic platform capable of multiplexed health profiling at point of care. The system is described as reaching attomolar sensitivity...
Antibiotic use reduction from vaccination programs – global review
A global scoping review of 74 primary studies found that vaccination programs measurably reduce antibiotic consumption and drug-resistant infections. By positioning immunization as upstream...